41 results about "Remission rate" patented technology

The invention provides application of a compound probiotic agent in preparing products for treating ulcerative colitis. The compound probiotic agent contains four probiotic lactic acid strains, namelylactobacillus casei Zhang, bifidobacterium zoonosus V9, lactobacillus plantarum P-8 and lactobacillus plantarum C2, and the probiotics all have good acid resistance, artificial gastrointestinal fluidtolerance and bile salt tolerance, and do not carry drug-resistant plasmids. The four probiotic strains are high in safety. The compound probiotic agent further contains prebiotics which can synergize with the probiotics, and then the probiotic function of the probiotics is ensured. Accordingly, the compound probiotic agent has remarkable curative effect on the ulcerative colitis, the probiotic function of an intestinal flora can be adjusted so as to make the intestinal flora healthy, and by taking the compound probiotic agent as an adjuvant drug for treating the ulcerative colitis, the compound probiotic agent has the advantages of being simple in treatment, high in remission rate, free of toxic or side effects and the like.

The invention discloses a soap pod saponin extract, a preparation method thereof and an application for curing lung cancer, liver cancer, stomach cancer, colorectal cancer and leukemia. The soap pod saponin extract uses fructus gleditsiae or fructus gleditsiae sinensis as the raw material and is prepared by the extraction of ethanol, and the separation and the purification of macroporous resin, and the content of total saponin of the extract is more than 60 percent. The saponin extract mainly comprises various pentacyclic triterpene saponin compounds, has obvious lethal effect on the clone of the leukemia progranulocyte HL-60 and the stomach cancer transferring lymphocyte SGC7901 of people, and has remarkably inhibited effect on the tumor of mice S180 and mice having the liver cancer. When capsules prepared by the extract are used for curing 40 examples having liver cancer, lung cancer, stomach cancer and colorectal cancer, the partial remission rate is 45 percent, and the partial remission and stabilization rate is 72.5 percent. When the capsules are used for curing 30 patients who have leukemia, the complete remission rate is 66.7 percent, and the total remission rate is 90 percent which is better than that of a single chemo-treatment group. The extract can obviously lighten the toxic side effect caused by the chemo-treatment.

The invention pertains to the field of biomedical technology, in particular to an orthotopic transplanted mouse liver cancer model which takes the research of the occurrence and development mechanisms of liver cancer and the development of anti-tumor drugs as the purposes, and the preparation method and the application thereof. The H22 cell strain of stable transfection EGFP is injected into the BALB / c mouse peritoneal cavity for amplification; the ascites is extracted from the H22 ascites cancer mouse peritoneal cavity, then cell separation is carried out and cell suspension is prepared; the mouse peritoneal cavity is opened, and the cell suspension is extracted by a micro-syringe to be injected into the mouse liver; a cotton bud with 75 percent alcohol is pressed on the needle hole till the surface of the liver does not bleed any more, and the needle hole is sealed by bonding agent; then the liver surface is washed by physiological saline, and layer separation is carried out and the peritoneal cavity is closed. The results show that the occurrence rate of mouse liver cancer is 100 percent and the natural remission rate is zero. The model is an ideal orthotopic liver cancer model which can be used in the research of the development and metastasis mechanisms of orthotopic liver cancer and can also be applicable to the development of anti-tumor drugs, the experimental treatment and diagnosis research of liver cancer.

The invention discloses a pharmaceutical composition for treating acute or chronic myeloblastic leukemia, which is characterized in that: it is made of dehydrated galactitol, kudzuvine root and pharmaceutical auxiliary materials. The composition in the invention has evident effect for treating leukemia, has an undoubted effect for treating lung cancer, multiple myeloma and nasopharyngeal carcinoma, especially has a preferable near term effect for treating chronic myeloblastic leukemia with a remission rate of 86%, has a higher effect for treating various lung cancer, and has lower poisonous and side effects.

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine decoction for curing limb pain caused by diabetic neuropathy, which is composed of corn stigma, Coptis chinensis, root of rehmannia, Radix Ophiopogonis, radix scrophulariae, Angelica sinensis, the root of red-rooted salvia, root of common peony, Ligusticum wallichii, leonurus, peach kernel paste, Astragalus mongholicus, rhizoma atractylodis, Asarum sieboldi Mig, Poria cocos, rhizoma alismatis, red flower, Caulis Spatholobi, corydalis tuber, Schisandra chinensis, liquorice and spina date seed. The traditional Chinese medicine decoction for curing limb pain caused by diabetic neuropathy is low in cost, high in curing rate and free of toxic and side effects and has the function of nourishing yin and engendering liquid, promoting blood circulation and removing stasis and dredging collateral and removing pain. The total effective rate is 95%, the remission rate is 80%, the improvement rate is 15% and the failure rate is 5%.

The invention discloses Chinese medicinal wine for treating rheumatoid arthritis and a preparation method thereof, belongs to the Chinese medicinal wine and a preparation method, and particularly relates to the Chinese medicinal wine for treating rheumatoid arthritis and the preparation method thereof. The medicament is prepared from the following raw materials in parts by weight: 25-30 parts of rhizoma notopterygii, 30-40 parts of radix angelicae pubescentis, 25-30 parts of medlar, 25-30 parts of dogwood flesh, 25-30 parts of eucommia, 25-30 parts of root of bidentate achyranthes, 15-20 parts of dipsacus root, 25-30 parts of rhizoma homalomenae, 25-30 parts of hedychiumvillosum, 25-30 parts of scutellaria baicalensis, 25-30 parts of rhizome corydalis, 25-30 parts of angelica, 25-30 parts of rhizoma coptidis, 25-30 parts of gastrodia elata, 15-20 parts of white peony root, 20-25 parts of root of red-rooted salvia, 25-30 parts of Talinum crassifolium, 25-30 parts of pawpaw, 25-30 parts of safflower and 3,000-3,500 parts of spirit with alcohol strength of 48 or 50 degrees. The Chinese medicinal wine has the beneficial effects of readily available raw materials, simple preparation method, clear curative effect, formula advantage, price advantage, process advantage, curative effect advantage and cure and remission rate of reaching 90 percent, and is novel Chinese medicinal wine for treating the rheumatoid arthritis at present.

The invention relates to an injection medicament for treating hyperthyroid, which comprises the following components by weight part: 2 to 5 milligrams of dexamethasone injection, 0.5 to 1 milligram of octreotide injection, and 10 to 20 milligrams of ciclosporin A. Immune preparations such as the dexamethasone injection, the octreotide injection, the ciclosporin A and the like are adopted for treating the hyperthyroid by locally injecting the thyroid, the volume of the tumid thyroid is remarkably shrunk, and the function of the thyroid basically recovers within two months, so the injection medicament has remarkable curative effect, and can remarkably improve the remission rate of hyperthyroid and reduce the rate of relapse. Serious abnormal change, hypothyroidism and parathyroid hypofunction are not caused, and laryngeal recurrent nerve injury is also not caused. Through more than 580 cases of clinical therapy in related hospitals, the volume of the tumid thyroid is remarkably shrunk after therapy, clinical symptoms disappear, allergic response and complications are not caused, the effective percentage is nearly 100 percent, and the cure rate is as high as 98 percent.

The invention discloses a waist joint zygapophysis cage and an implanting device thereof. The waist joint zygapophysis cage comprises an oblate spheroid, and both ends of the oblate spheroid are provided with an upper cylinder and a lower cylinder respectively which have coincided center shafts and the same diameter; the oblate spheroid is 6 mm in diameter and 4 mm in height; the diameters of the upper cylinder and the lower cylinder are 2 mm, the upper cylinder is 2 mm in height, and the lower cylinder is 1mm in height; and the oblate spheroid, the upper cylinder and the lower cylinder are made of cortical bone materials of adult thighbone. The implanting device comprises a positioning device, a working channel, a straight drill, a spherical drill and an implanting machine. The waist joint zygapophysis cage has the advantages of improving the medium and long term fusion rates of the lumbar facet joint and the remission rate of postoperative symptoms, eliminating the loosening and breaking of bolts and reducing side effects of bolts such as neurologic damage and the like caused by epidural rupture and vertebral canal puncture. The implanting device has the advantages of simple structure, easy operation and good use effect.

The invention relates to a traditional Chinese medicine for treating prostatic cancer, characterized by comprising the following medicinal raw materials in proportion: 10-30 parts of astragalus root, 10-15 parts of angelica, 8-12 parts of euryale seed, 6-8 parts of antler, 10-15 parts of glossy privet fruit, 10-20 parts of gardenia fruit, 10-30 parts of honeysuckle, 10-15 parts of weeping forsythia, 6-10 parts of java brucea fruit, 8-12 parts of red peony root, 6-10 parts of hemp root, 10-15 parts of lotus root node, 10-14 parts of madder root, 8-10 parts of longhairy antenoron herb, 8-12 parts of climbing fern spore, 10-18 parts of mulberry bark and 6-10 parts of licorice. After the medicinal raw materials are selected, mixed and soaked, water is added for decocting, one dose of decoction is 200ml, 100ml of decoction is taken orally twice per day respectively in the morning and at night, and one course of treatment lasts for 10 days. The invention has the beneficial effects that the overall treatment concept for strengthening the body resistance and resisting cancer has the following therapeutic principles of: invigorating qi and nourishing the blood, strengthening the kidney and expelling toxin, dissipating blood stasis and alleviating pain, promoting blood circulation and arresting bleeding, and regulating internal secretion; diagnosis and treatment are based on an overall analysis of the illness and the condition of a patient clinically according to different syndromes; and the recurrence, spread and metastasis of cancer are effectively controlled. The medicine has quick curative effect, high remission rate and no toxic side effect.

The invention discloses a pharmaceutical composition for treating leukaemia. The composition is made from the following raw materials: 10-50 parts of anhydrogalactitol, 30-50 parts of angelica, 30-50 parts of astragalus root, 15-50 parts of ginseng, 15-50 parts of red sage root, 15-50 parts of pilose asiabell root and 10-30 parts of figwirt root. The pharmaceutical composition has obvious effects on treating the leukaemia, certain curative effect on lung cancer, multiple myeloma, nasopharyngeal carcinoma and the like, especially good short-term curative effect on chronic granulocytic leukemia with a remission rate up to 86%, higher effective rate on various lung cancers and less toxic side effect.

The invention belongs to the technical field of medicines and particularly relates to a medicine for treating wegner granulomatosis combined with pseudotumot of orbit and a preparation method thereof. The medicine for treating wegner granulomatosis combined with pseudotumot of orbit is prepared from the following traditional Chinese medicine raw material medicines in parts by weight: 80-120 parts of angelica sinensis, 40-60 parts of liquorice, 130-170 parts of double blossom, 130-170 parts of radix scrophulariae, 16-24 parts of caltrop and 40-60 parts of selfheal. The total remission rate of the medicine for treating wegner granulomatosis combined with pseudotumot of orbit is 62%.

The invention discloses a traditional Chinese medicinal preparation for treating primary thrombocytopenia, which is prepared from the following raw material medicaments in part by weight: 10 to 50 parts of cassia bark, 30 to 50 parts of large-headed atractylodes rhizome, 30 to 50 parts of astragalus, 15 to 50 parts of szechwon tangshen root, 15 to 50 parts of root of red-rooted salvia, 15 to 50 parts of szechuan lovage rhizome and 10 to 30 parts of glossy ganoderma. The traditional Chinese medicinal preparation has the obvious curative effect on leukemia, has a certain curative effect on lung cancer, myeloma multiplex, nasopharyngeal darcinoma and the like and particularly has the good short-term curative effect on primary thrombocytopenic purpura, and has 86 percent of remission rate and low toxic and side effect.

The invention discloses a method for detecting the expression level of a BCL11A gene by using a Q-PCR technology and an application of the method. Amplification primers and probes of BCL11A and GAPDH are designed, and a Q-PCR amplification system is optimized. According to the invention, the established Q-PCR detection method for detecting the expression level of the BCL11A gene is proved to be capable of precisely detecting the expression level of BCL11A in a sample of a leukemia patient and analyzing the correlation between the expression level of BCL11A and treatment remission rate and the correlation between the expression level of BCL11A and prognosis. The method disclosed by the invention can be used for detecting the expression level of the BCL11A gene and providing the basis for diagnosis, treatment remission and prognostic evaluation for leukemia patients in clinic.

The present invention discloses a drug for treating acute leukemia and refractory acute leukemia, the components of the pharmaceutical raw materials of the drug composition are: 5 to 20 parts by weight of thunberg fritillary bulb, 5 to 20 parts by weight of fourstamen stephania root and 2 to 12 parts by weight of Szechuan lovage rhizome. The present invention provides an application of the thunberg fritillary bulb composition in the adjuvant chemotherapy to improve the clinical efficacy of the refractory acute leukemia; the present invention carries out a large amount of experiments, which takes the clinical remission rate as the clinical efficacy evaluation index and takes the heart, liver, renal function etc. as the safety indexes and the detection indexes, the results prove that the thunberg fritillary bulb composition has better clinical efficacy in the adjuvant chemotherapy to improve the clinical efficacy of the refractory acute leukemia and also has the better clinical medication safety.

The invention discloses a traditional Chinese medicine for treating myelodysplastic syndromes. The traditional Chinese medicine is prepared from the following raw materials in parts by mass: 5-15g of living earthworms, 20-40g of codonopsis pilosula, 20-40g of astragalus membranaceus, 8-16g of white atractylodes rhizome and 7-15g of indigo naturalis. The traditional Chinese medicine is decocted by water and then is taken according to a prescription principle of traditional Chinese medicine; clinical application verifies that the total effective rate is 98.67%, and the remission rate is 90.67% and the traditional Chinese medicine has no obvious toxic side effect.

The invention relates to a combined medicine for curing treatment-resistant depression (TRD), which is characterized in that the combined medicine comprises paroxetine and sodium valproate. The invention also provides applications of the combined medicine. The invention has the advantages that the research on the TRD synergia strategy is provided for the first time in China, the combined medicine of paroxetine and sodium valproate, and the applications of the combined medicine in the preparation of medicine for curing the TRD are provided for the first time, the paroxetine combined with the sodium valproate for curing the TRD has higher remission rate, and the tolerance is high, so that the combined medicine can be taken as the new intensive treatment scheme for curing the TRD.

The invention relates to the technical field of medicines, in particular to a stem cell preparation and an application of the stem cell preparation in preparing a drug for treating chronic nephritis. The provided stem cell preparation is prepared through resuspension of umbilical cord mesenchymal stem cells by the aid of normal saline, the content of urine protein of a patient and the number of urine erythrocyte are reduced by inhibiting expression of T cell surface antigen CD8 and secretion of INF-gamma and up-regulating secretion of IL-4 of T lymphocyte of peripheral blood, so that the effect for treating chronic nephritis is realized, the effective rate of treatment can reach 88%, and the remission rate can reach 54%.

The present invention discloses a biochip for assisting large intestine cancer targeted therapy. Meanwhile, the present invention further discloses a use method of the biochip and a preparation method for a bio-chip detection sample. According to the present invention, multiple gene loci can be simultaneously detected, such that the biochip of the present invention has characteristics of excellent performance and exact treatment effect prediction compared with the traditional single-detection K-RAS mutation chip, the large intestine cancer treatment remission rate of Erbitux can be increased to 41% from 36%, and the disease control rate can be increased to 82% from 76%; and due to use of immune microarray detection, advantages of short time consuming, high sensitivity, high accuracy, high throughput, and low cost of individual detection are provided.

The invention relates to a traditional Chinese medicine formula composition for treating scapulohumeral periarthritis. The composition is characterized by being prepared from, by weight, 30-50 g of kun astragalus, 20-60 g of codonopsis pilosula, 20-40 g of cornus pulp, 10-30 g of ramulus mori, 10-40 g of cassia twig, 10-20 g of eucommia ulmoides, 10-30 g of angelica sinensis, 10-30 g of ligusticum wallichii, 10-25 g of radix paeoniae alba and 10-30 g of fresh ginger. The composition is prepared based on a pure traditional Chinese medicine formula, and is high in remission rate, good in curative effect, capable of becoming effective quickly, capable of treating both symptoms and root causes, and free of side effect.

The invention relates to the field of medicine, in particular to a combination drug for treating leukemia. The drug comprises chidamide and DCAG medicine which are used for administration simultaneously, respectively or successively and have an effective dose, and the DCAG medicine is a combining drug of decitabine, cytarabinem, aclarubicin and granulocyte colony-stimulating factors. The inventionprovides the application of chidamide-combined DCAG in the preparation of a drug for treating the acute myeloid leukemia, and the combination drug has the following beneficial effects: the recurrentrefractory problem of an existing AML-combined chemotherapy scheme is solved, the complete remission (CR) of patients suffering from recurrent refractory acute myeloid leukemia which is treated by thecombination drug is up to 43.6%, and the objective remission rate (ORR) is up to 58.2%.

The invention relates to a traditional Chinese medicine composition for treating recurrence of meningiomas after the surgery. The traditional Chinese medicine is characterized by comprising the following raw materials: 6-9g of frankincense, 6-8g of myrrh, 3-6g of stiff silkworm, 6-10g of salvia chinensis, 6-10g of curcuma zedoary, 3-6g of edible tulip, 6-8g of ligusticum wallichii, 6-8g of red-rooted salvia root, 4-6g of radix angelicae, 6-8g of red peony root, 4-6g of caulis spatholobi, 3-6g of sculellaria barbata, 3-6g of self heal, 4-6g of mangnolia officinalis, 4-6g of coix seed, 6-8g of codonopsis pilosula, 4-6g of angelica, 4-6g of tuckahoe, 4-6g of rhizoma alismatis and 4-6g of liquorice. The traditional Chinese medicine composition has the beneficial effects of promoting blood circulation for removing blood stasis, supporting the healthy energy, resolving hard lump and inducing diuresis to alleviate edema. The traditional Chinese medicine composition has the characteristics of good treatment effect, high remission rate, low cost and low toxic side effect. The recurrence of meningiomas is dialectically treated according to different symptom patterns in clinical science.

The invention relates to traditional Chinese medicine formula composition for treating bromhidrosis. The traditional Chinese medicine formula composition for treating the bromhidrosis is characterized by comprising medicinal materials by weight as follows: 150-300 g of dried tangerine peels, 150-250 g of Mingchi tea, 20-60 parts of star anise, 20-60 parts of pepper and 5-20 g of Tie Guanyin tea. The composition adopts a pure traditional Chinese medicine formula, has a high remission rate, is good in curative effect, takes effect fast, can treat both the symptoms and the root causes of the disease and doesn't have toxic or side effects.

The invention discloses a pharmaceutical composition for treating leukemia, which is made from dehydrated dulcitol 10-50 parts, Chinese angelica 30-50 parts, astragalus 30-50 parts, ginseng 15-50 parts, red sange root 15-50 parts, pilose asiabell root 15-50 parts, and figwirt root 10-30 parts. The invention achieves a substantial effect for treating leukemia, has a certain effect in treatment of lung cancer, multiple myeloma and nasopharyngeal carcinoma, achieves a better near term effect especially to chronic myelogenous leukemia with a remission rate of 86%, and has a higher effective ratio to various lung cancer with lower toxic and side effect.

The invention relates to an oral pill, and in particular to an oral pill for treating impotence and a preparation method of the oral pill. According to a specific prescription, the finished oral pillproduct is prepared from radix aconiti lateralis preparata, dried ginger, herba cistanche, medical pipefish, hippocampus japonicus, Chinese leek seeds, flos carthami, centipedes, radix morindae officinalis, herba cynomorii, radix polygoni multiflori preparata, silkworm moth, fructus cnidii, fructus alpiniae oxyphyllae, fructus psoraleae, seeds of Chinese dodder, fructus rosae laevigatae, herba epimedii, antler tablets, cassia bark, radix ginseng, spongilla fragilla fragilis leidy, Chinese chives, radix angelicae sinensis, rhizoma polygonati, crocus sativus, colla corii asini, antlet glue, tortoise-shell glue and the like by virtue of such processes as conducting airing, conducting crushing, conducting heating, conducting mixing and the like. The oral pill provided by the invention is low in cost of medicinal raw materials, cheap in process, simple in preparation method and free from toxic and side effects; the syndrome of the impotence in patients can be effectively improved; a remission rate can reach 93.5%; and a non-symptomatic rate is lower than 10%, lower than that of other medicines.

The invention provides a Chinese medicine preparation for treating mammary gland proliferation diseases and a preparation method thereof. The Chinese medicine preparation is mainly formed by fourteen Chinese medicine materials such as rhizoma cyperi, curcuma zedoary, rheum officinale, leech, white paeony root, rhizoma sparganii, Paris polyphylla, ground beetle, Scutellaria baicalensis, almond, peach kernel, prepared rehmannia root, licorice root and the like, is a pure Chinese medicine preparation, is used to mainly treat mammary gland proliferation diseases caused by liver stagnation, blood stasis and qi stagnation, not only can relive stagnation and soften hardness but also can regulate menstruation, invigorate blood circulation and relieve pain, and has the advantages of obvious curative effect and small toxic side effect. According to clinical experiments, the Chinese medicine preparation is proved to be a safe, effective and quick-effect Chinese medicine preparation, the effectiveness is above 95 percent, the remission rate is above 85 percent, the clinical effect is obvious and no relapse occurs after treatment.

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine decoction for curing limb pain caused by diabetic neuropathy, which is composed of corn stigma, Coptis chinensis, root of rehmannia, Radix Ophiopogonis, radix scrophulariae, Angelica sinensis, the root of red-rooted salvia, root of common peony, Ligusticum wallichii, leonurus, peach kernel paste, Astragalus mongholicus, rhizoma atractylodis, Asarum sieboldi Mig, Poria cocos, rhizoma alismatis, red flower, Caulis Spatholobi, corydalis tuber, Schisandra chinensis, liquorice and spina date seed. The traditional Chinese medicine decoction for curing limb pain caused by diabetic neuropathy is low in cost, high in curing rate and free of toxic and side effects and has the function of nourishing yin and engendering liquid, promoting blood circulation and removing stasis and dredging collateral and removing pain. The total effective rate is 95%, the remission rate is 80%, the improvement rate is 15% and the failure rate is 5%.

The invention belongs to the technical field of medicines, and particularly relates to a medicine for treating a wegener's granulomatosis combined orbital pseudotumor and a preparation method thereof. The medicine for treating the medicine for treating a wegener's granulomatosis combined orbital pseudotumor is prepared from, by weight, 80-120 parts of amaranthaceae aerva sanguinolenta, 40-60 parts of fructus terminaliae billericae, 130-170 parts of oldenlandia diffusa, 130-170 parts of arcangelisia loureiri, 16-24 parts of tsuchiuri and 40-60 parts of selaginella involvens. The medicine is used for treating the wegener's granulomatosis combined orbital pseudotumor, and the total remission rate is 62%.